AGTC rides gene therapy interest to raise $37.5m in Series B
This article was originally published in Scrip
Applied Genetic Technologies Corporation (AGTC) has benefitted from increased interest and acceptance for gene therapy with a $37.5 million Series B financing round for rare genetic lung and eye disease therapies administered via the company's proprietary, non-pathogenic adeno-associated virus (AAV) delivery system.
You may also be interested in...
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.
Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.